GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codon AG (CHIX:CNWKd) » Definitions » ROCE %

Codon AG (CHIX:CNWKD) ROCE % : -118.47% (As of Jun. 2022)


View and export this data going back to 2015. Start your Free Trial

What is Codon AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Codon AG's annualized ROCE % for the quarter that ended in Jun. 2022 was -118.47%.


Codon AG ROCE % Historical Data

The historical data trend for Codon AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codon AG ROCE % Chart

Codon AG Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -64.59 -11.19 -39.17 -45.73 -33.35

Codon AG Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -53.83 -42.45 -50.01 -22.79 -118.47

Codon AG ROCE % Calculation

Codon AG's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=-8.255/( ( (29.011 - 2.853) + (26.316 - 2.975) )/ 2 )
=-8.255/( (26.158+23.341)/ 2 )
=-8.255/24.7495
=-33.35 %

Codon AG's ROCE % of for the quarter that ended in Jun. 2022 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2022 )  (Q: Dec. 2021 )(Q: Jun. 2022 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2022 )  (Q: Dec. 2021 )(Q: Jun. 2022 )
=-21.194/( ( (26.316 - 2.975) + (15.563 - 3.123) )/ 2 )
=-21.194/( ( 23.341 + 12.44 )/ 2 )
=-21.194/17.8905
=-118.47 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2022) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Codon AG  (CHIX:CNWKd) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Codon AG ROCE % Related Terms

Thank you for viewing the detailed overview of Codon AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Codon AG (CHIX:CNWKD) Business Description

Traded in Other Exchanges
N/A
Address
Warthestrasse 21, Teltow, DEU, 14513
Codon AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells (autologous chondrocytes). CODON's method is currently used in over 200 clinics in Germany and more than 14,000 patients have already been treated.

Codon AG (CHIX:CNWKD) Headlines

No Headlines